Silo Pharma to Highlight Patented Nose-to-Brain Drug Delivery Technology for PTSD at 2026 Nasal Innovation Forum
Silo Pharma will participate in the IPAC-RS 2026 Nasal Innovation Forum on September 16-17, 2026, in Jersey City, New Jersey, to showcase its patented nose-to-brain drug delivery technology. CEO Eric Weisblum framed the forum as a chance to engage with nasal drug development experts as the company advances SPC-15, its preclinical PTSD candidate. The release recaps preclinical data showing SPC-15's formulation and device met specifications for assay, impurities, pH, and microbiological quality over nine months, with six-month accelerated stability data consistent with long-term results.
Key figures
- Forum dates
- September 16-17, 2026
- Stability period months
- 9
- Accelerated stability months
- 6
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.